Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 1:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 184 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: GW572016 Clear all
Completed Phase 1 Interventional

Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)

NCT00148902
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib, docetaxel
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
Detroit, Michigan • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 3, 2026, 1:39 PM EDT
Completed Phase 1 Interventional

Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2

NCT00544804
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
lapatinib ditosylate, gene expression analysis, diagnostic laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 3, 2026, 1:39 PM EDT
Completed Phase 2 Interventional Results available

Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck

NCT01044433
View directory record Official record
Conditions
Head and Neck Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions
lapatinib ditosylate, capecitabine
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 3, 2026, 1:39 PM EDT
Withdrawn Phase 1 Interventional

A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors

NCT00682279
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
oral topotecan (SK&F-104864); lapatinib (GW572016)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 3, 2026, 1:39 PM EDT
Completed Phase 1 Interventional

Study To Assess Long Term Safety Of Pazopanib

NCT00387205
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Pazopanib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
15
States / cities
Duarte, California • Santa Monica, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 3, 2026, 1:39 PM EDT
Completed Phase 1 Interventional

Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease

NCT02581124
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, Lapatinib
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 3, 2026, 1:39 PM EDT
Withdrawn Phase 2 Interventional

Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer

NCT01700010
View directory record Official record
Conditions
Urothelial Cancer, Bladder Cancer
Interventions
Lapatinib and Paclitaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Oct 3, 2026, 1:39 PM EDT
Completed Phase 1 Interventional Results available

A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema

NCT00439179
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
cohort 1, cohort 2, cohort 3, cohort 4
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 3, 2026, 1:39 PM EDT
Completed Phase 1 Interventional

Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients

NCT00158782
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
GW786034, lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 3, 2026, 1:39 PM EDT
Terminated Not applicable Interventional Results available

Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast

NCT00857714
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
lapatinib
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 3, 2026, 1:39 PM EDT
Completed Phase 1 Interventional Results available

Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer

NCT00470847
View directory record Official record
Conditions
Breast Cancer, Brain Metastases
Interventions
Lapatinib, Whole Brain Radiation, Herceptin
Drug · Procedure
Lead sponsor
Nancy Lin, MD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 3, 2026, 1:39 PM EDT
Completed Phase 1 Interventional

Lapatinib With Sirolimus or Metformin

NCT01087983
View directory record Official record
Conditions
Advanced Cancers
Interventions
Lapatinib, Sirolimus, Metformin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2015 · Synced Oct 3, 2026, 1:39 PM EDT
Completed No phase listed Observational

Chemotherapeutic Agents in Brain/Breast

NCT00795678
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
capecitabine, cyclophosphamide, doxorubicin hydrochloride, gemcitabine hydrochloride, lapatinib ditosylate, paclitaxel, vinorelbine ditartrate, Trastuzumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 3, 2026, 1:39 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer

NCT00359190
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
8
States / cities
Miami, Florida • Durham, North Carolina • Allentown, Pennsylvania + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 3, 2026, 1:39 PM EDT
Completed Phase 1 Interventional

Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer

NCT00379509
View directory record Official record
Conditions
Breast Cancer
Interventions
lapatinib ditosylate, TdT-mediated dUTP nick end labeling assay, gene expression analysis, microarray analysis, immunohistochemistry staining method, biopsy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 3, 2026, 1:39 PM EDT
Completed Phase 1 Interventional

A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients

NCT00821054
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Buffalo, New York • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 3, 2026, 1:39 PM EDT
Completed Phase 3 Interventional Results available

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

NCT00667251
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, docetaxel, lapatinib ditosylate, paclitaxel
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
53
States / cities
Anchorage, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 3, 2026, 1:39 PM EDT
Completed Phase 4 Interventional Results available

A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval

NCT01328054
View directory record Official record
Conditions
Cancer
Interventions
lapatinib, placebo matching lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Detroit, Michigan • Lebanon, New Hampshire • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2016 · Synced Oct 3, 2026, 1:39 PM EDT
Terminated Phase 1 Interventional Results available

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

NCT00634088
View directory record Official record
Conditions
Locally Advanced or Metastatic Breast Cancer
Interventions
Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg, Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg, Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg, Ixabepilone + Lapatinib + Capecitabine
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 3, 2026, 1:39 PM EDT
Completed Phase 2 Interventional Results available

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

NCT00558103
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib, Pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
17
States / cities
Long Beach, California • Sacramento, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 3, 2026, 1:39 PM EDT
Completed Phase 2 Interventional

Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer

NCT00105950
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
8
States / cities
Miami, Florida • Chicago, Illinois • Zion, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 3, 2026, 1:39 PM EDT
Terminated Phase 2 Interventional Results available

Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy

NCT00225758
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Lapatinib
Drug
Lead sponsor
Gary Schwartz
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
Aurora, Colorado • Lebanon, New Hampshire • Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 3, 2026, 1:39 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer

NCT02213042
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Trastuzumab, Aromatase Inhibitors (AIs)
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Mobile, Alabama • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 3, 2026, 1:39 PM EDT
Terminated Phase 2 Interventional Results available

Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

NCT00479856
View directory record Official record
Conditions
Relapsed Breast Cancer, Neoplasms, Breast
Interventions
Lapatinib, Capecitabine, Docetaxel, nab-Paclitaxel
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
28
States / cities
Hot Springs, Arkansas • Anaheim, California • Burbank, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 3, 2026, 1:39 PM EDT